Your AI-Trained Oncology Knowledge Connection!

Publication

Video

Supplements and Featured Publications

BTK Inhibitors in B-Cell Lymphomas
Volume1
Issue 1

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

Author(s):

Lori A. Leslie, MD

In Partnership With:

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the utility of BTK inhibitors in B-cell malignancies.

BTK inhibitors target an enzyme that is necessary for B​-cell growth, says Leslie. ​Moreover, there are several approved indications ​for BTK inhibitors in chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma ​(MCL), and ​Waldenström macroglobulinemia.

Notably, ibrutinib (Imbruvica) ​and acalabrutinib (Calquence) ​are 2 BTK inhibitors that are approved for patients with B-cell malignancies. Moreover, zanubrutinib (Brukinsa) is currently approved in relapsed/refractory MCL and is the subject of ongoing investigation in other B-cell malignancies, Leslie concludes. 

Articles in this issue
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Building on Current Understandings of BTK Inhibition in CLL, MCL
Building on Current Understandings of BTK Inhibition in CLL, MCL
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Yufei Liu, MD, PhD
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Jacob Moyer, BS, of Mayo Clinic
Alfred L. Garfall, MD
COOMBS
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Related Content
R/R DLBCL | Image Credit: © LASZLO - stock.adobe.com
March 20th 2025

FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL

Andre Henri Goy, MD
December 18th 2024

Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD

Orca-T in Hematologic Malignancies
March 17th 2025

Orca-T Improves cGVHD-Free Survival in Advanced Hematologic Malignancies

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Cema-Cel in R/R LBCL | Image Credit: © LASZLO – stock.adobe.com
March 11th 2025

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.
March 9th 2025

Five Under 5: Top Oncology Videos for the Week of 3/2